KLP Kapitalforvaltning AS Makes New $318,000 Investment in Astrana Health, Inc. (NASDAQ:ASTH)

KLP Kapitalforvaltning AS acquired a new position in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,100 shares of the company's stock, valued at approximately $318,000.

Several other institutional investors have also added to or reduced their stakes in ASTH. State Street Corp acquired a new position in shares of Astrana Health in the 3rd quarter worth approximately $91,966,000. Geode Capital Management LLC bought a new position in Astrana Health during the third quarter worth $58,995,000. FMR LLC acquired a new position in Astrana Health in the third quarter valued at $48,413,000. Principal Financial Group Inc. bought a new stake in Astrana Health during the third quarter valued at $13,383,000. Finally, Royce & Associates LP grew its holdings in Astrana Health by 122.3% during the 4th quarter. Royce & Associates LP now owns 255,552 shares of the company's stock worth $8,058,000 after acquiring an additional 140,584 shares during the period. 52.77% of the stock is currently owned by institutional investors.

Astrana Health Stock Up 0.9 %

ASTH stock traded up $0.29 during midday trading on Thursday, reaching $32.22. 293,710 shares of the company's stock traded hands, compared to its average volume of 270,767. Astrana Health, Inc. has a 52 week low of $23.12 and a 52 week high of $63.20. The company has a market cap of $1.61 billion, a price-to-earnings ratio of 24.78, a P/E/G ratio of 1.37 and a beta of 1.04. The firm's fifty day moving average price is $32.47 and its 200-day moving average price is $40.18. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The business had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. As a group, sell-side analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ASTH has been the topic of a number of recent analyst reports. Truist Financial dropped their price objective on Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Barclays began coverage on Astrana Health in a report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price target on the stock. Bank of America reduced their price objective on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Robert W. Baird dropped their target price on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Finally, Macquarie upgraded shares of Astrana Health to a "hold" rating in a report on Monday, December 16th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.